To access the full text documents, please follow this link: http://hdl.handle.net/2445/120875
dc.contributor | Universitat de Barcelona |
---|---|
dc.contributor.author | Gatell, José M. |
dc.contributor.author | Morales Ramirez, Javier O. |
dc.contributor.author | Hagins, Debbie P. |
dc.contributor.author | Thompson, Melanie |
dc.contributor.author | Keikawus, Arasteh |
dc.contributor.author | Hoffmann, Christian |
dc.contributor.author | Rugina, Sorin |
dc.contributor.author | Osiyemi, Olayemi |
dc.contributor.author | Escoriu, Simona |
dc.contributor.author | Dretler, Robin |
dc.contributor.author | Harvey, Charlotte |
dc.contributor.author | Xu, Xia |
dc.contributor.author | Teppler, Hedy |
dc.date | 2018-03-19T15:11:10Z |
dc.date | 2018-03-19T15:11:10Z |
dc.date | 2014 |
dc.date | 2018-03-19T15:11:10Z |
dc.identifier.citation | 1758-2652 |
dc.identifier.citation | 649144 |
dc.identifier.uri | http://hdl.handle.net/2445/120875 |
dc.format | 2 p. |
dc.format | application/pdf |
dc.language.iso | eng |
dc.publisher | BioMed Central |
dc.relation | Reproducció del document publicat a: https://doi.org/10.7448/IAS.17.4.19532 |
dc.relation | Journal of the International AIDS Society, 2014, vol. 17, num. Suppl 3, p. 19532 |
dc.relation | https://doi.org/10.7448/IAS.17.4.19532 |
dc.rights | cc-by (c) Gatell, José M. et al., 2014 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.subject | Infeccions per VIH |
dc.subject | Antiretrovirals |
dc.subject | Assaigs clínics de medicaments |
dc.subject | HIV infections |
dc.subject | Antiretroviral agents |
dc.subject | Drug testing |
dc.title | Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.description.abstract |